Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Legend Biotech (LEGN) EBT Margin (2019 - 2025)

Legend Biotech filings provide 7 years of EBT Margin readings, the most recent being 6.43% for Q4 2025.

  • On a quarterly basis, EBT Margin fell 2815.0% to 6.43% in Q4 2025 year-over-year; TTM through Dec 2025 was 8.21%, a 1701.0% increase, with the full-year FY2025 number at 27.47%, down 226.0% from a year prior.
  • EBT Margin hit 6.43% in Q4 2025 for Legend Biotech, up from 14.35% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 308.16% in Q1 2023 to a low of 1612.82% in Q2 2022.
  • Median EBT Margin over the past 5 years was 63.91% (2022), compared with a mean of 203.55%.
  • Biggest five-year swings in EBT Margin: tumbled -116018bps in 2022 and later skyrocketed 134167bps in 2023.
  • Legend Biotech's EBT Margin stood at 226.53% in 2021, then tumbled by -117bps to 491.16% in 2022, then skyrocketed by 100bps to 0.0% in 2023, then skyrocketed by 11754083bps to 21.72% in 2024, then plummeted by -130bps to 6.43% in 2025.
  • The last three reported values for EBT Margin were 6.43% (Q4 2025), 14.35% (Q3 2025), and 48.93% (Q2 2025) per Business Quant data.